OR WAIT null SECS
Jonathan A. Bernstein, MD: University of Cincinnati
November 19, 2025
Article
New phase 2 data reveals povorcitinib effectively reduces itch and hives in chronic spontaneous urticaria, showing promise as a treatment option.